Epigenetic control of thymic CD4+ T lymphocyte development in humans – paving the way for new iPSC-derived T cell therapies. (EpiC4TT)

Leibniz Competition Collaborative Excellence

The project focuses on characterizing the epigenetic regulatory mechanisms required for the efficient in vitro differentiation of CD4+ T-lymphocytes from human induced pluripotent stem cells (iPSCs). These regulatory mechanisms are influenced by the three-dimensional structure of the genome (the epigenome) and can be specifically modified using advanced molecular methods (epigenetic editing). This approach enables the production of cells of a specific type and with desired functions, e.g., for therapeutic applications.

Cooperation partner: Berlin Institute of Health

Project term: since 2024